Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (2)

2021

  1. ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer

    Molecular Cancer Therapeutics, Vol. 20, Núm. 4, pp. 641-654

2020

  1. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 39, pp. 24415-24426